SANOFI highlights recent partnership to generate Real-World Evidence

The International Niemann-Pick Disease Registry (INPDR) announced a new collaboration with Sanofi, by giving controlled access to anonymized registry information via INPDR’s research “Gateway” platform. This collaboration will provide Sanofi with Real-World Evidence that will support evaluation and decision making on the use of olipudase alfa to manage Acid Sphingomyelinase Deficiency (ASMD). INPDR is the largest active database about the diagnosis, management, and progression of the inherited lysosomal storage disorders known as Acid Sphingomyelinase Deficiency and Niemann-Pick type C Disease (NPC).